Story

Latigo Biotherapeutics Shares Rise 17% in Market Debut After Upsized $346M IPO

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Latigo Biotherapeutics Shares Rise 17% in Market Debut After Upsized $346M IPO
Text size
Background

Shares of Latigo Biotherapeutics (NASDAQ: LTGO) surged 17% in their trading debut Friday after the company raised $345.6 million in an upsized initial public offering. The strong market reception highlights investor interest in the company's development of non-opioid pain medication.

Offering Details

Latigo Biotherapeutics sold 19.2 million shares at $18 per share, the top of its marketed range of $16 to $18, according to a company announcement. The offering was increased from the initially planned 16 million shares, a sign of robust demand from institutional investors.

The gross proceeds of the offering total $345.6 million before deducting underwriting discounts and commissions. Underwriters also have a 30-day option to purchase up to an additional 2.88 million shares. The offering is expected to close on August 10, 2026.

Market Debut

Latigo's stock opened for trading on the Nasdaq Global Select Market at $21 per share. The successful IPO gives the Thousand Oaks, California-based company a market valuation of approximately $1.3 billion, based on the number of outstanding shares listed in its filings.

Sample IUX Markets – In-articleAd

Company Background

Latigo Biotherapeutics is a clinical-stage company focused on developing non-addictive pain medicines. Its lead product candidate, LTG-001, is an oral Nav1.8 inhibitor designed to treat acute pain without the risks associated with opioids. The company is backed by Blue Owl Capital Inc.

The IPO was managed by a syndicate of banks, with key roles including:

  • Goldman Sachs & Co. LLC
  • Jefferies
  • Leerink Partners
  • Guggenheim Securities

Read next

More on Stocks
Back to latest news

LATEST